Revolutionizing drug development for Parkinson's disease by using imaging biomarkers analysis tools.
It is difficult to diagnose Parkinson’s disease, and the only way to confirm diagnosis is postmortem. The new imaging AI tools could be the answer.
At RSNA 2022, our team discussed the latest advances in imaging trials software, including state-of-the-art digital biomarkers algorithms.
It is difficult to diagnose Parkinson’s disease, and the only way to confirm diagnosis is postmortem. The new imaging AI tools could be the answer.
Prof. Russ Hornbeck shares insights on Alzheimer's research and imaging technology through his experience in medical imaging, discussing the DIAN...
Sucessfully passed to 2nd phase FICHe grant for novel work on Quantification and Analytics for Parkinson’s disease Mint Labs’ team is happy to...